PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc (“Oxford Biomedica”), a leading gene and cell therapy group, today announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed.

PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies
John Dawson, CEO, Oxford Biomedica

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system. The programme will initially focus on CAR-T therapy and aims to develop next-generation cell therapies with significantly improved efficacy and durability.

This collaboration with Oxford Biomedica, a global pioneer in cell and gene therapies, is further recognition of the power of SITESEEKER®, offering an exciting opportunity to discover and accelerate the development of clinical stage products. The natural complementarity between SITESEEKER® and LentiVector® offers great promise for this and future collaborations between the two companies.”

Dr Chris Torrance, CEO, PhoreMost

We are excited to apply this next-generation technology to our LentiVector® platform. The collaboration has the potential to deliver more effective CAR-T therapies, and we look forward to working closely with the PhoreMost team.”

John Dawson, CEO, Oxford Biomedica

SITESEEKER® exploits protein shape diversity to find functionally active peptides linked to any chosen disease setting, significantly enhancing the power of phenotypic screening and translation into therapeutic modalities. Based on proprietary protein interference, or ‘PROTEINi®’, technology, SITESEEKER® is able to systematically probe the entire proteome in a live cell environment to identify and exploit novel drug targets.

Oxford Biomedica is a world-leading pioneer of cell and gene therapies. Its LentiVector® platform enables the successful development of breakthrough gene and cell-based medicines, and through collaborations with pharmaceutical partners, has delivered the first FDA and EMA approved CAR-T cell therapy.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PhoreMost. (2020, November 10). PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies. News-Medical. Retrieved on September 21, 2021 from https://www.news-medical.net/news/20201110/PhoreMost-and-Oxford-Biomedica-collaborate-to-develop-next-generation-CAR-T-cell-therapies.aspx.

  • MLA

    PhoreMost. "PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies". News-Medical. 21 September 2021. <https://www.news-medical.net/news/20201110/PhoreMost-and-Oxford-Biomedica-collaborate-to-develop-next-generation-CAR-T-cell-therapies.aspx>.

  • Chicago

    PhoreMost. "PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies". News-Medical. https://www.news-medical.net/news/20201110/PhoreMost-and-Oxford-Biomedica-collaborate-to-develop-next-generation-CAR-T-cell-therapies.aspx. (accessed September 21, 2021).

  • Harvard

    PhoreMost. 2020. PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies. News-Medical, viewed 21 September 2021, https://www.news-medical.net/news/20201110/PhoreMost-and-Oxford-Biomedica-collaborate-to-develop-next-generation-CAR-T-cell-therapies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
PhoreMost announces two key appointments to strengthen leadership team